




Pregnancy & Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure

Dr. Sarah Mulkey, MD, PhD | May 3, 2023
Prenatal Pediatrics Institute, Children's National Hospital

Outline

- 
- Introduction
 - Study Details
 - Partner With Us!
 - Questions

Introduction

Study Team



Sarah Mulkey

MD, PhD (she/her)

Prenatal and Neonatal
Neurologist, Division of
Prenatal Pediatrics

Co-Director, Congenital
Infection Program



Roberta DeBiasi

MD, MS (she/her)

Chief, Division of Pediatric
Infectious Diseases

Co-Director, Congenital
Infection Program



Meagan Williams

MSPH, CCRC (she/her)

Clinical Research
Coordinator, Divisions of
Pediatric Infectious Diseases
and Prenatal Pediatrics



Above: Children's National Hospital, Washington, DC

Top left image: NPR article highlighting the Congenital Infection Program team

Bottom left image: Publication by Mulkey et al. in JAMA Pediatrics (2020)

Right image: Congenital Infection Program website

Congenital Infection Program

The Congenital Infection Program specializes in evaluating and researching outcomes of children with antenatal exposure to infectious agents.





iStock


Lyme Disease and Pregnancy

There is some scientific agreement that *B. burgdorferi* can be vertically transmitted to a developing fetus and may cause congenital infection.

However, to date, no studies have systematically investigated pregnancy and long-term child neurodevelopment outcomes following in utero exposure to *B. burgdorferi*.

New Study: Now Recruiting!

We are conducting a pilot study to assess feasibility of evaluating **outcomes of pregnancies affected by Lyme disease infection** and the brain development of **fetuses and children who were exposed to Lyme disease in utero**.


Children's National

Volunteers Needed

Children's National Hospital is looking for **pregnant volunteers who have been diagnosed with Lyme disease during their current pregnancy**. You will be paid for your time.

Study Overview:

We are enrolling pregnant volunteers with Lyme disease to follow their pregnancy and the neurodevelopment of their infants through age 18 months. If you join this study, we will collect information about you during and after pregnancy and monitor your baby's development. The study includes questionnaires, one fetal MRI and ultrasound, one infant MRI and ultrasound, two in-person neurology evaluations, and two blood draws.


Why is this study being done?

There are many questions about Lyme disease infection during pregnancy that have not yet been answered.

We are doing this study to learn about how Lyme disease during pregnancy impacts babies' brain growth and neurodevelopment.

Contact Us!

To learn more or join the study, scan the QR code or contact our study team!



Sarah Mulkey, MD, PhD.
202-476-3388
mewilliams@childrensnational.org



Funding for this project was provided by a grant from the Clinical Trials Network supported by the Steven and Alexandra Cohen Foundation.

Study Details

Overview

We will recruit participants with Lyme disease or Post-Treatment Lyme Disease Syndrome **during pregnancy** and follow their infants' development **through 18 months** of age.



This pilot study will be the first study to evaluate the long-term impact of Lyme disease exposure on pregnancy, brain development, and childhood neurodevelopment.

Study Aims

**Assess child
neurodevelopment**

1

To determine whether infants exposed to *B. burgdorferi* in utero have abnormal neurodevelopmental outcomes to age 18 months

**Evaluate brain
abnormalities**

2

To evaluate whether there are abnormalities in the fetal and neonatal brains of *B. burgdorferi*-exposed fetuses and infants

**Assess pregnancy
outcomes**

3

To assess pregnancy outcomes associated with gestational exposure to Lyme disease based on the timing of Lyme disease exposure, symptom onset, and treatment

Participants

- **All** participants must be pregnant, >18 years of age, capable of comprehending the study, and available for long-term follow-up requirements*

* Note: Travel to Children's National Hospital for a fetal and infant MRI is strongly preferred, but not required. Participants will be excluded from the MRI portion of the study if they have health issues or metallic implant that precludes them from undergoing MRI.

Cohort #1:

Lyme disease
diagnosis during
pregnancy

Cohort #2:

Post-Treatment
Lyme Disease
Syndrome during
pregnancy

Two Cohorts

Cohort #1:

Lyme disease
diagnosis during
pregnancy

About Cohort #1:

- Currently **pregnant**
- Meet CDC criteria for clinical/ laboratory diagnosis of any stage of **Lyme disease occurring during any trimester of current pregnancy**

Cohort #2:

Post-Treatment
Lyme Disease
Syndrome during
pregnancy

About Cohort #2:

- Currently **pregnant**
- **Completed treatment for any stage of Lyme disease between 6 months and 3 years ago**
 - Lyme disease previously diagnosed using CDC criteria for clinical/laboratory diagnosis
- Currently with **active symptoms** attributed to clinician-diagnosed Post-Treatment Lyme Disease Syndrome (PTLDS) or Chronic Lyme

Two Cohorts

Cohort #1:

Lyme disease
diagnosis during
pregnancy

About Cohort #1:

- Currently pregnant
- Meet CDC criteria for clinical/ laboratory diagnosis of any stage of Lyme disease occurring during any trimester of current pregnancy




Cohort #2:

Post-Treatment
Lyme Disease
Syndrome during
pregnancy

About Cohort #2:

- Currently pregnant
- Completed treatment for any stage of Lyme disease between 6 months and 3 years ago
 - Lyme disease previously diagnosed using CDC criteria for clinical/laboratory diagnosis
- Currently with active symptoms attributed to clinician-diagnosed Post-Treatment Lyme Disease Syndrome (PTLDS) or Chronic Lyme

Study Timeline

-  **Pregnancy** (enrollment + one in-person visit, optional qualitative interview)
-  **Delivery** (data sharing with birth hospital, placental pathology)
-  **Infancy** (two in-person visits, three online visits)

Ongoing: Monitoring of clinical and demographic factors that may impact outcomes (Lyme/PTLDS, medical history, mental health, nutrition, SES, etc.)

Schedule of Events: Pregnancy

PREGNANCY



MRI and ultrasound
(2nd or 3rd trimester)

Antibody testing and
cytokine panel

Monitoring of Lyme/
PTLDS, pregnancy, and
fetal growth

Optional: Qualitative
interview

DELIVERY



Delivery hospital shares:

- newborn records,
including infant
length and weight
- labor and delivery
records
- placental pathology
reports

Additional analysis of
placenta

INFANCY



Infant brain MRI,
cranial ultrasound,
neurological exams

Antibody testing and
cytokine panel

Ongoing monitoring of
infant growth and
neurodevelopment
(ASQ, WIDEA, AIMS)

ONGOING: Monitoring of clinical and demographic factors that may impact outcomes
(SES, nutrition, medical history, Lyme/PTLDS history, mental health, etc.)

Schedule of Events: Delivery

PREGNANCY



MRI and ultrasound
(2nd or 3rd trimester)

Antibody testing and
cytokine panel

Monitoring of Lyme/
PTLDS, pregnancy, and
fetal growth

Optional: Qualitative
interview

DELIVERY



Delivery hospital shares:

- newborn records,
including infant
length and weight
- labor and delivery
records
- placental pathology
reports

Additional analysis of
placenta

INFANCY



Infant brain MRI,
cranial ultrasound,
neurological exams

Antibody testing and
cytokine panel

Ongoing monitoring of
infant growth and
neurodevelopment
(ASQ, WIDEA, AIMS)

ONGOING: Monitoring of clinical and demographic factors that may impact outcomes
(SES, nutrition, medical history, Lyme/PTLDS history, mental health, etc.)

Schedule of Events: Infancy

PREGNANCY



MRI and ultrasound
(2nd or 3rd trimester)

Antibody testing and
cytokine panel

Monitoring of Lyme/
PTLDS, pregnancy, and
fetal growth

Optional: Qualitative
interview

DELIVERY



Delivery hospital shares:

- newborn records,
including infant
length and weight
- labor and delivery
records
- placental pathology
reports

Additional analysis of
placenta

INFANCY



Infant brain MRI,
cranial ultrasound,
neurological exams

Antibody testing and
cytokine panel

Ongoing monitoring of
infant growth and
neurodevelopment
(ASQ, WIDEA, AIMS)

ONGOING: Monitoring of clinical and demographic factors that may impact outcomes
(SES, nutrition, medical history, Lyme/PTLDS history, mental health, etc.)

Partner With Us!

We Need Your Help!

If you...

- know a pregnant person who might be eligible to participate in this study
- have colleagues whose clients might be pregnant with Lyme disease or PTLDS
- are interested in sharing this research with your organization's audience or stakeholders

Please refer them to our research team!

**If you have patients who may be eligible,
please contact us!**

Sarah Mulkey, MD, PhD (PI):
sbmulkey@childrensnational.org

Research team:
Meagan Williams, MSPH:
mewilliams@childrensnational.org
cnhlymestudy@gmail.com



Tip: Take a photo of this
slide to reference later!

Recruitment Toolkit

If you are interested in helping our team find study participants, we made you a **Recruitment Toolkit**!

The Toolkit includes our study recruitment flyer, social media templates, important links, FAQs, and more to help you share information about our study with your patients, clients, and colleagues!



Link on the next slide →

Stay Connected

Scan the QR code or visit the website below to stay connected with our research team!



<http://eepurl.com/ipNdhl>

Make sure to select
"Yes" if you want
access to our
Recruitment Toolkit!

Questions?



- **Email the team:** cnhlymestudy@gmail.com
- **Stay connected:** Scan the QR code to sign up for our email newsletter!
- **Thank you to our funders!** This study was funded by a grant from the Clinical Trials Network supported by the Steven and Alexandra Cohen Foundation.